CAPR News and Press, Capricor Therapeutics Inc. From 11/14/23

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...

Capricor Therapeutics Inc. (CAPR) is expected to report $-0.27 for Q3 2023

2023-11-13 17:35:40 ET More on Capricor Therapeutics Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy Capricor: Q4 2023 Interim Analysis For DMD Treatment Makes This A Must Watch ...

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial result...

Toronto, Ontario--(Newsfile Corp. - November 7, 2023) - Caprock Mining Corp. (CSE:CAPR) (" Caprock " or the " Company ") is pleased to announce the results of a high-resolution, drone-based magnetics survey that was recently completed at its Ackley Lithium-Tin-Molybdenum-REEs property (" Ackley "...

Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce that Mr. Jim Kirke has joined the Company's Board of Directors, effective immediately. Mr. Kirke is a Canadian Chartered Professional Accountant with o...

2023-10-25 12:39:22 ET Summary Recent dip in CAPR's stock price following update on regulatory pathway for CAP-1002 and cash raise represents a buying opportunity. Completion of enrollment of Cohort A of ongoing Phase 3 trial of CAP-1002 is expected in Q4 2023, topline results in ...

SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company ...

-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy- -Company’s StealthX™ Technology Shows Promise of Exosome-Based Delivery of ASOs- SAN DIEGO, Oct. 10, 2023 (GLOB...

2023-10-04 16:06:31 ET An estimated 250,000-500,000 people experience a %SpinalCordInjury (SCI) annually, with roughly 17,000 new cases in the US and 27,000 in Europe each year, leaving many of those people permanently confined to a wheelchair. What if there were a way to repair the dam...